Belantamab mafodotin – Uses, Dosage, Side Effects, Interactions

Last updated: February 8, 2026Reviewed date: February 8, 2026Reading time: 47 min read
Patient Tools

Read, save, and share this guide

Use these quick tools to make this medical article easier to read, print, save, or share with a family member.

Belantamab mafodotin - Uses, Dosage, Side Effects, Interactions
Patient Mode

Understand this article easily

Switch between simple English and easy Bangla patient notes. This is for education and does not replace a doctor consultation.

Belantamab mafodotin is an anti-B-cell maturation antigen-antibody conjugated to a microtubule inhibitor to treat relapsed or refractory multiple myeloma. Belantamab mafodotin, or GSK2857916, is a fucosylated monoclonal antibody that targets B cell maturation antigen conjugated to the microtubule disrupter monomethyl auristatin-F (MMAF).[rx]Belantamab mafodotin was granted...

For severe symptoms, danger signs, pregnancy, child illness, or sudden worsening, seek urgent medical care.

বাংলা রোগী নোট এখনো যোগ করা হয়নি। পোস্ট এডিটরে “RX Bangla Patient Mode” বক্স থেকে সহজ বাংলা সারাংশ যোগ করুন।

এই তথ্য শিক্ষা ও সচেতনতার জন্য। এটি ডাক্তারি পরীক্ষা, রোগ নির্ণয় বা প্রেসক্রিপশনের বিকল্প নয়।

Article Summary

Belantamab mafodotin is an anti-B-cell maturation antigen-antibody conjugated to a microtubule inhibitor to treat relapsed or refractory multiple myeloma. Belantamab mafodotin, or GSK2857916, is a fucosylated monoclonal antibody that targets B cell maturation antigen conjugated to the microtubule disrupter monomethyl auristatin-F (MMAF).[rx]Belantamab mafodotin was granted FDA approval on 5 August 2020. Mechanism of action Belantamab mafodotin is a humanized IgG1κ monoclonal antibody against the B-cell maturation...

Key Takeaways

  • This article explains Mechanism of action in simple medical language.
  • This article explains Indication in simple medical language.
  • This article explains Contraindication in simple medical language.
  • This article explains Dosage in simple medical language.
Educational health guideWritten for patient understanding and clinical awareness.
Reviewed content workflowUse writer and reviewer profiles for stronger trust.
Emergency safety firstUrgent warning signs are highlighted below.

Seek urgent medical care if you notice

These warning signs are general safety guidance. Local emergency numbers and clinical judgment should always come first.

  • Severe symptoms, breathing difficulty, fainting, confusion, or rapidly worsening illness.
  • New weakness, severe pain, high fever, or symptoms after a serious injury.
  • Any symptom that feels urgent, unusual, or unsafe for the patient.
1

Emergency now

Use emergency care for severe, sudden, rapidly worsening, or life-threatening symptoms.

2

See a doctor

Book a professional medical evaluation if symptoms persist, worsen, recur often, affect daily activities, or occur in a high-risk patient.

3

Learn safely

Use this article to understand possible causes, tests, treatment options, prevention, and questions to ask your clinician.

Before reading

RX Patient Tools

Use these quick guides before reading the article, or return to them when you need help preparing questions for a doctor.

Start here Choose the right pathway for symptoms, reports, medicines, or urgent warning signs. Disease article roadmap Read this topic step by step: meaning, symptoms, warning signs, diagnosis, treatment, prevention, and follow-up. Treatment planner Prepare questions about treatment choices, benefits, risks, side effects, and follow-up. Family & caregiver guide Organize symptoms, reports, medicines, questions, and follow-up safely. Nutrition & diet guide Prepare food, hydration, supplement, and medicine-timing questions safely. Prevention guide Organize risk factors, protective habits, screening, and warning signs. Recovery guide Prepare a safe plan for activity, rehabilitation, warning signs, and follow-up.
Definition

Belantamab mafodotin is an anti-B-cell maturation antigen-antibody conjugated to a microtubule inhibitor to treat relapsed or refractory multiple myeloma. Belantamab mafodotin, or GSK2857916, is a fucosylated monoclonal antibody that targets B cell maturation antigen conjugated to the microtubule disrupter monomethyl auristatin-F (MMAF).[rx]Belantamab mafodotin was granted FDA approval on 5 August 2020.

Mechanism of action

Belantamab mafodotin is a humanized IgG1κ monoclonal antibody against the B-cell maturation antigen (BCMA) conjugated with a cytotoxic agent, maleimidocaproyl monomethyl auristatin F (mcMMAF).[rx] The antibody-drug conjugate binds to BCMA on myeloma cell surfaces causing cell cycle arrest and inducing antibody-dependent cellular cytotoxicity.[rx]

Belantamab mafodotin, or GSK2857916, is a fucosylated monoclonal antibody that targets B cell maturation antigen (BCMA) conjugated to the microtubule disrupter monomethyl auristatin-F (MMAF).[rx] Afucosylation of the Fc region of monoclonal antibodies enhances binding to the Fc region, which enhances antibody-dependant cell-mediated cytotoxicity.[rx]

BCMA is uniquely expressed in CD138-positive myeloma cells.[rx] Targeting BCMA allows belantamab mafodotin to be highly selective in its delivery of MMAF to multiple myeloma cells[rx] Belantamab mafodotin binds to BCMA, is internalized into cells, and releases MMAF.[rx]

The MMAF payload binds to tubulin, stopping the cell cycle at the DNA damage checkpoint between the G2 and M phases, resulting in apoptosis.[rx]

Belantamab mafodotin treats multiple myeloma through antibody dependant cell-mediated cytotoxicity as well as G2/M cell cycle arrest.[rx] It has a narrow therapeutic index due to the incidence of adverse effects, and a long duration of action as it is given every 3 weeks.[rx] Patients should be counseled regarding the risk of keratopathy.[rx]

Indication

  • Belantamab mafodotin is indicated in the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.[rx]
  • Relapsed Or Refractory Multiple Myeloma
  • Belantamab mafodotin is indicated for the treatment of adults with relapsed or refractory multiple myeloma who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent
  • For treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.

Use in Cancer

Belantamab mafodotin-blmf is approved to treat:

Belantamab mafodotin-blmf is only available as part of a special program called Blenrep REMS (Risk Evaluation and Mitigation StrategiesExit Disclaimer).

This use is approved under FDA’s Accelerated Approval Program. As a condition of approval, a confirmatory trial(s) must show that belantamab mafodotin-blmf provides a clinical benefit in these patients.

Contraindication

The following conditions are contraindicated with this drug. Check with your physician if you have any of the following:

  • decreased blood platelets
  • a decrease in sharpness of vision called reduced visual acuity
  • pregnancy
  • a patient who is producing milk and breastfeeding

Dosage

Strengths: blmf 100 mg

Multiple Myeloma

  • 2.5 mg/kg (of actual body weight) IV over 30 minutes once every 3 weeks until disease progression or unacceptable toxicity

Renal Dose Adjustments

  • Mild (CrCl 60 to less than 90 mL/min) or moderate (CrCl 30 to less than 60 mL/min) renal impairment: No adjustment recommended.
    Severe (CrCl 15 to less than 30 mL/min) or end-stage (CrCl less than 15 mL/min) renal impairment: Data not available

Liver Dose Adjustments

  • Mild hepatic impairment (total jaundice. সহজ বাংলা: জন্ডিসে বাড়তে পারে এমন হলুদ রঞ্জক।" data-rx-term="bilirubin" data-rx-definition="Bilirubin is a yellow pigment that can build up in jaundice. সহজ বাংলা: জন্ডিসে বাড়তে পারে এমন হলুদ রঞ্জক।">bilirubin less than or equal to the upper limit of normal [ULN] and aspartate aminotransferase (AST) greater than ULN or total bilirubin 1 to less than or equal to 1.5 x ULN and any AST): No adjustment recommended.
    Moderate or severe hepatic impairment (total jaundice. সহজ বাংলা: জন্ডিসে বাড়তে পারে এমন হলুদ রঞ্জক।" data-rx-term="bilirubin" data-rx-definition="Bilirubin is a yellow pigment that can build up in jaundice. সহজ বাংলা: জন্ডিসে বাড়তে পারে এমন হলুদ রঞ্জক।">bilirubin greater than 1.5 x ULN and any AST): Data not available

Dose Adjustments

DOSE MODIFICATIONS FOR ADVERSE REACTIONS:

  • The recommended dose reduction for adverse reactions is: 1.9 mg/kg IV once every 3 weeks; discontinue therapy in patients who are unable to tolerate a dose of 1.9 mg/kg.

CORNEAL ADVERSE REACTIONS:

  • The recommended dosage modifications for corneal adverse reactions are based on both corneal examination findings and changes in best-corrected visual acuity (BCVA).
  • Determine the dose modification based on the worst finding in the worst affected eye. Worst finding should be based on either a corneal examination finding or a change in visual acuity per the Keratopathy and Visual Acuity (KVA) scale.

DOSE MODIFICATIONS FOR CORNEAL ADVERSE REACTIONS PER THE KVA SCALE CORNEAL ADVERSE REACTION:

  • GRADE 1 (mild superficial keratopathy with or without symptoms; change in BCVA: decline from baseline of 1 line on Snellen Visual Acuity: Continue therapy at the current dose.
  • GRADE 2: (moderate superficial keratopathy with or without patchy microcyst-like deposits, sub-epithelial haze [peripheral], or a new peripheral stromal opacity; change in BCVA: decline from baseline of 2 or 3 lines on Snellen Visual Acuity and not worse than 20/200): Withhold therapy until improvement in both corneal examination findings and change in BCVA to Grade 1 or less; resume at the same dose.
  • GRADE 3 (severe superficial keratopathy with or without diffuse microcyst-like deposits, sub-epithelial haze (central), or a new central stromal opacity; change in BCVA: decline from baseline of 2 or 3 lines on Snellen Visual Acuity and not worse than 20/200): Withhold therapy until improvement in both corneal examination findings and change in BCVA to Grade 1 or less; resume at a reduced dose.
  • GRADE 4 (corneal epithelial defect [e.g., corneal ulcers]; change in BCVA: Snellen Visual Acuity worse than 20/200): Consider permanent discontinuation of therapy; if continuing therapy, withhold this drug until improvement in both corneal examination findings and change in BCVA to Grade 1 or better; resume at a reduced dose.

DOSE MODIFICATIONS FOR OTHER ADVERSE REACTIONS:
platelet count, which can increase bleeding risk. সহজ বাংলা: প্লাটিলেট কম।" data-rx-term="thrombocytopenia" data-rx-definition="Thrombocytopenia means low platelet count, which can increase bleeding risk. সহজ বাংলা: প্লাটিলেট কম।">THROMBOCYTOPENIA:

  • Platelet counts 25,000 to less than 50,000/mcL: Consider withholding this drug and/or reducing the dose.
  • Platelet count less than 25,000/mcL: Withhold this drug until platelet count improves to Grade 3 or less; consider resuming at a reduced dose.

INFUSION-RELATED REACTIONS:

  • GRADE 2 or 3: Interrupt infusion and provide supportive care; when symptoms resolve, resume infusion rate at 50% of the previous rate.
  • GRADE 4: Permanently discontinue therapy and provide emergency care.

OTHER ADVERSE REACTIONS:

  • GRADE 3: Withhold therapy until improvement to Grade 1 or less; consider resuming at a reduced dose.
  • GRADE 4: Consider permanent discontinuation of therapy; if continuing therapy, withhold this drug until improvement to Grade 1 or less and resume at a reduced dose.

Side Effects

The Most Common

  • nausea
  • constipation
  • diarrhea
  • loss of appetite
  • joint or pain: Back pain means pain in the spine, muscles, discs, joints, or nerves of the back. সহজ বাংলা: পিঠ/কোমরের ব্যথা।" data-rx-term="back pain" data-rx-definition="Back pain means pain in the spine, muscles, discs, joints, or nerves of the back. সহজ বাংলা: পিঠ/কোমরের ব্যথা।">back pain
  • tiredness
  • unusual bleeding or bruising
  • shortness of breath, chest pain, cough

More common

  • Black, tarry stools
  • bleeding gums
  • blood in urine or stools
  • blurred vision or any other change in vision
  • body aches or pain
  • change in color vision
  • chest pain or tightness
  • chills
  • confusion
  • constipation
  • cough
  • decreased frequency or amount of urine
  • depression
  • difficulty seeing at night
  • difficulty with swallowing
  • dizziness
  • dry eye
  • dry mouth
  • ear congestion
  • eye redness, irritation, or pain
  • fainting
  • fast heartbeat

Rare

  • fever
  • pain in the head or upper neck. সহজ বাংলা: মাথাব্যথা।" data-rx-term="headache" data-rx-definition="Headache means pain in the head or upper neck. সহজ বাংলা: মাথাব্যথা।">headache
  • incoherent speech
  • increased sensitivity of the eyes to sunlight
  • increased thirst
  • increased urination
  • lightheadedness or faintness
  • loss of appetite
  • loss of voice
  • low blood pressure or pulse
  • lower back or side pain
  • metallic taste
  • muscle weakness
  • nausea
  • pinpoint red spots on the skin
  • pounding in the ears
  • rapid, shallow breathing
  • runny or stuffy nose
  • skin rash, itching, or hives
  • sneezing
  • sore throat
  • stomach pain
  • swelling in the face, hands, or lower legs
  • trouble breathing
  • unconsciousness
  • unusual bleeding or bruising
  • unusual tiredness or weakness
  • vomiting
  • weight gain or loss

Drug Interaction

Pregnancy and Lactation

 US FDA pregnancy category: Not assigned.

Pregnancy

The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help healthcare providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out. Based on its mechanism of action, this drug can cause fetal harm when administered to a pregnant woman, because it contains a genotoxic compound (the microtubule inhibitor, MMAF) and targets actively dividing cells. Human immunoglobulin G (IgG) is known to cross the placenta; therefore, this drug has the potential to be transmitted from the mother to the developing fetus.

Lactation

There are no data on the presence of this drug in human milk or the effects on the breastfed child or milk production. Because of the potential for serious adverse reactions in the breastfed child, advise women not to breastfeed during therapy and for 3 months after.

How should this medicine be used?

Belantamab mafodotin-blmf comes as a powder to be mixed with liquid and injected intravenously (into a vein) over 30 minutes by a doctor or nurse in a hospital or medical facility. It is usually given once every 3 weeks. The cycle may be repeated as recommended by your doctor. The length of your treatment depends on how well your body responds to the medication and any side effects that you experience.

A doctor or nurse will watch you closely while you are receiving the medication to be sure you are not having a serious reaction to the medication. Tell your doctor or nurse immediately if you experience any of the following symptoms: chills; flushing; itching or rash; shortness of breath, cough, or wheezing; tiredness; fever; dizziness or lightheadedness; or swelling of your lips, tongue, throat, or face.

Your doctor may reduce your dose or temporarily or permanently stop your treatment. This depends on how well the medication works for you and the side effects you experience. Be sure to tell your doctor how you are feeling during your treatment with belantamab mafodotin-blmf.

What special precautions should I follow?

Before receiving belantamab mafodotin-blmf injection,

  • tell your doctor and pharmacist if you are allergic to belantamab mafodotin-blmf, any other medications, or any of the ingredients in belantamab mafodotin-blmf injection. Ask your pharmacist or check the Medication Guide for a list of the ingredients.
  • tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Your doctor may need to change the doses of your medications or monitor you carefully for side effects.
  • tell your doctor if you have or have ever had bleeding problems.
  • tell your doctor if you are pregnant, plan to become pregnant, or plan to father a child. You should not start receiving belantamab mafodotin-blmf injection until a pregnancy test has shown that you are not pregnant. If you are a woman who is able to become pregnant, you must use effective birth control during your treatment and for 4 months after your final dose. If you are male with a female partner who could become pregnant, you must use effective birth control during your treatment and for 6 months after your final dose. Talk to your doctor about methods of birth control that will work for you. If you or your partner become pregnant while receiving belantamab mafodotin-blmf injection, call your doctor. Belantamab mafodotin-blmf injection may harm the fetus.
  • tell your doctor if you are breastfeeding. Do not breastfeed during your treatment and for 3 months after your final dose.
  • you should know that this medication may decrease fertility in men and women. Talk to your doctor about the risks of receiving belantamab mafodotin-blmf injection.

When to Contact Your Doctor or Health Care Provider

Contact your health care provider immediately, day or night, if you should experience any of the following symptoms:

  • Fever of 100.4º F (38º C) or higher, chills (possible signs of infection)
  • Infusion reactions include:
    • Redness of your face
    • Itching or rash
    • Shortness of breath, coughing, or wheezing
    • Swelling of your lips, tongue, throat, or face
    • Dizziness
    • Feel like passing out
    • Tiredness
    • Feel like your heart is racing (palpitations)
  • Nausea (interferes with the ability to eat and is unrelieved with prescribed medication)
  • Diarrhea (4-6 episodes in a 24-hour period)
  • Unusual bleeding or bruising
  • Black or tarry stools, or blood in your stools
  • Blood in the urine
  • Pain or burning with urination
  • Extreme fatigue (unable to carry on self-care activities)
  • Mouth sores (painful redness, swelling or ulcers)

Always inform your healthcare provider if you experience any unusual symptoms.

References

Doctor visit helper

Prepare before seeing a doctor

A simple rural-patient checklist to help you explain symptoms clearly, ask better questions, and avoid unsafe self-treatment.

Safety note: This is not a prescription or diagnosis. For severe symptoms, pregnancy danger signs, children with serious illness, chest pain, breathing difficulty, stroke-like weakness, or major injury, seek urgent care.

Which doctor may help?

Start with a registered doctor or the nearest qualified health center.

What to tell the doctor

  • Write when the problem started and how it changed.
  • Bring old prescriptions, investigation reports, and current medicines.
  • Write allergies, pregnancy status, diabetes, kidney/liver disease, and major past illnesses.
  • Bring one family member if the patient is weak, elderly, confused, or a child.

Questions to ask

  • What is the most likely cause of my symptoms?
  • Which danger signs mean I should go to hospital quickly?
  • Which tests are necessary now, and which can wait?
  • How should I take medicines safely and what side effects should I watch for?
  • When should I come for follow-up?

Tests to discuss

  • Vital signs: temperature, pulse, blood pressure, oxygen saturation
  • Basic physical examination by a clinician
  • CBC, urine test, blood sugar, or imaging only when clinically needed

Avoid these mistakes

  • Do not use antibiotics, steroid tablets/injections, or strong painkillers without proper medical advice.
  • Do not hide pregnancy, kidney disease, ulcer, allergy, or blood thinner use.
  • Do not delay emergency care when danger signs are present.

Medicine safety and first-aid guide

This section is for patient education only. It does not replace a doctor, pharmacist, or emergency care.

Safe first steps

  • Avoid heavy lifting, sudden bending, and prolonged bed rest.
  • Use comfortable posture and gentle movement as tolerated.
  • Discuss physiotherapy, X-ray, or MRI only when clinically needed.

OTC medicine safety

  • For mild back pain, pain-relief medicine may be discussed with a doctor or pharmacist.
  • Avoid repeated painkiller use if you have kidney disease, stomach ulcer, uncontrolled blood pressure, or are taking blood thinners.

Avoid these mistakes

  • Do not start antibiotics without a proper medical decision.
  • Do not use steroid tablets or injections casually for quick relief.
  • Do not delay emergency care because of home remedies.

Get urgent help if

  • Back pain with leg weakness, numbness around private area, loss of urine/stool control, fever, cancer history, or major injury needs urgent care.
Medicine names, dose, and timing must be decided by a qualified clinician or pharmacist after checking age, pregnancy, allergy, other diseases, and current medicines.

For rural patients and family caregivers

Patient health record and symptom diary

Write your symptoms, medicines already taken, test results, and questions before visiting a doctor. This note stays on your device unless you print or copy it.

Doctor to discuss: Orthopedic / spine specialist, physical medicine doctor, or qualified clinician
Tests to discuss with doctor
  • Neurological examination for leg power, sensation, reflexes, and straight leg raise
  • X-ray only if injury, deformity, long-lasting pain, or doctor suspects bone problem
  • MRI discussion if severe nerve symptoms, weakness, bladder/bowel problem, or persistent symptoms
Questions to ask
  • What is the most likely cause of my symptoms?
  • Which warning signs mean I should go to emergency care?
  • Which tests are really needed now?
  • Which medicines are safe for my age, pregnancy status, allergy, kidney/liver/stomach condition, and current medicines?
  • Is physiotherapy, posture correction, or activity modification needed?

Emergency warning signs such as chest pain, severe breathing difficulty, sudden weakness, confusion, severe dehydration, major injury, or loss of bladder/bowel control need urgent medical care. Do not wait for online information.

Safe pathway to proper treatment

Care roadmap for: Belantamab mafodotin – Uses, Dosage, Side Effects, Interactions

Use this simple roadmap to understand the next safe steps. It is educational and does not replace examination by a doctor.

Go to emergency care if you notice:
  • Severe or rapidly worsening symptoms
  • Breathing difficulty, chest pain, fainting, confusion, severe weakness, major injury, or severe dehydration
Doctor / service to discuss: Qualified healthcare provider; specialist depends on symptoms and examination.
  1. Step 1

    Check danger signs first

    If danger signs are present, seek emergency care and do not wait for online information.

  2. Step 2

    Record the symptom story

    Write when symptoms started, severity, medicines already taken, allergies, pregnancy status, and test results.

  3. Step 3

    Visit a qualified clinician

    A doctor, nurse, or qualified healthcare provider can examine you and decide which tests or treatment are needed.

  4. Step 4

    Do only useful tests

    Do tests after clinical assessment. Avoid unnecessary tests, random antibiotics, or repeated medicines without diagnosis.

  5. Step 5

    Follow up and return early if worse

    If symptoms worsen, new warning signs appear, or treatment is not helping, return for review quickly.

Rural patient practical tips
  • Take a written symptom diary and all previous prescriptions/test reports.
  • Do not hide medicines already taken, even herbal or over-the-counter medicines.
  • Ask which warning signs mean urgent referral to hospital.

This roadmap is for education. A real diagnosis and treatment plan requires history, examination, and clinical judgment.

RX Patient Help

Ask a health question safely

Write your symptom story. A health professional or site editor can review it before any answer is prepared. This box is not for emergency care.

Emergency first: Severe chest pain, breathing trouble, unconsciousness, stroke signs, severe injury, heavy bleeding, or rapidly worsening symptoms need urgent local medical care now.

Frequently Asked Questions

Mechanism of action Belantamab mafodotin is a humanized IgG1κ monoclonal antibody against the B-cell maturation antigen (BCMA) conjugated with a cytotoxic agent, maleimidocaproyl monomethyl auristatin F (mcMMAF).[rx] The antibody-drug conjugate binds to BCMA on myeloma cell surfaces causing cell cycle arrest and inducing antibody-dependent cellular cytotoxicity.[rx] Belantamab mafodotin, or GSK2857916, is a fucosylated monoclonal antibody that targets B cell maturation antigen (BCMA) conjugated to the microtubule disrupter monomethyl auristatin-F (MMAF).[rx] Afucosylation of the Fc region of monoclonal antibodies enhances binding to the Fc region, which enhances antibody-dependant cell-mediated cytotoxicity.[rx] BCMA is uniquely expressed in CD138-positive myeloma cells.[rx] Targeting BCMA allows belantamab mafodotin to be highly selective in its delivery of MMAF to multiple myeloma cells[rx] Belantamab mafodotin binds to BCMA, is internalized into cells, and releases MMAF.[rx] The MMAF payload binds to tubulin, stopping the cell cycle at the DNA damage checkpoint between the G2 and M phases, resulting in apoptosis.[rx] Belantamab mafodotin treats multiple myeloma through antibody dependant cell-mediated cytotoxicity as well as G2/M cell cycle arrest.[rx] It has a narrow therapeutic index due to the incidence of adverse effects, and a long duration of action as it is given every 3 weeks.[rx] Patients should be counseled regarding the risk of keratopathy.[rx] Indication Belantamab mafodotin is indicated in the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.[rx] Relapsed Or Refractory Multiple Myeloma Belantamab mafodotin is indicated for the treatment of adults with relapsed or refractory multiple myeloma who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent For treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. Use in Cancer Belantamab mafodotin-blmf is approved to treat: Multiple myeloma that has relapsed (come back) or is refractory (does not respond to treatment). It is used in adults who have received at least four previous treatments that included an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulating agent. Belantamab mafodotin-blmf is only available as part of a special program called Blenrep REMS (Risk Evaluation and Mitigation StrategiesExit Disclaimer). This use is approved under FDA’s Accelerated Approval Program. As a condition of approval, a confirmatory trial(s) must show that belantamab mafodotin-blmf provides a clinical benefit in these patients. Contraindication The following conditions are contraindicated with this drug. Check with your physician if you have any of the following: decreased blood platelets a decrease in sharpness of vision called reduced visual acuity pregnancy a patient who is producing milk and breastfeeding Dosage Strengths: blmf 100 mg Multiple Myeloma 2.5 mg/kg (of actual body weight) IV over 30 minutes once every 3 weeks until disease progression or unacceptable toxicity Renal Dose Adjustments Mild (CrCl 60 to less than 90 mL/min) or moderate (CrCl 30 to less than 60 mL/min) renal impairment: No adjustment recommended. Severe (CrCl 15 to less than 30 mL/min) or end-stage (CrCl less than 15 mL/min) renal impairment: Data not available Liver Dose Adjustments Mild hepatic impairment (total bilirubin less than or equal to the upper limit of normal [ULN] and aspartate aminotransferase (AST) greater than ULN or total bilirubin 1 to less than or equal to 1.5 x ULN and any AST): No adjustment recommended. Moderate or severe hepatic impairment (total bilirubin greater than 1.5 x ULN and any AST): Data not available Dose Adjustments DOSE MODIFICATIONS FOR ADVERSE REACTIONS: The recommended dose reduction for adverse reactions is: 1.9 mg/kg IV once every 3 weeks; discontinue therapy in patients who are unable to tolerate a dose of 1.9 mg/kg. CORNEAL ADVERSE REACTIONS: The recommended dosage modifications for corneal adverse reactions are based on both corneal examination findings and changes in best-corrected visual acuity (BCVA). Determine the dose modification based on the worst finding in the worst affected eye. Worst finding should be based on either a corneal examination finding or a change in visual acuity per the Keratopathy and Visual Acuity (KVA) scale. DOSE MODIFICATIONS FOR CORNEAL ADVERSE REACTIONS PER THE KVA SCALE CORNEAL ADVERSE REACTION: GRADE 1 (mild superficial keratopathy with or without symptoms; change in BCVA: decline from baseline of 1 line on Snellen Visual Acuity: Continue therapy at the current dose. GRADE 2: (moderate superficial keratopathy with or without patchy microcyst-like deposits, sub-epithelial haze [peripheral], or a new peripheral stromal opacity; change in BCVA: decline from baseline of 2 or 3 lines on Snellen Visual Acuity and not worse than 20/200): Withhold therapy until improvement in both corneal examination findings and change in BCVA to Grade 1 or less; resume at the same dose. GRADE 3 (severe superficial keratopathy with or without diffuse microcyst-like deposits, sub-epithelial haze (central), or a new central stromal opacity; change in BCVA: decline from baseline of 2 or 3 lines on Snellen Visual Acuity and not worse than 20/200): Withhold therapy until improvement in both corneal examination findings and change in BCVA to Grade 1 or less; resume at a reduced dose. GRADE 4 (corneal epithelial defect [e.g., corneal ulcers]; change in BCVA: Snellen Visual Acuity worse than 20/200): Consider permanent discontinuation of therapy; if continuing therapy, withhold this drug until improvement in both corneal examination findings and change in BCVA to Grade 1 or better; resume at a reduced dose. DOSE MODIFICATIONS FOR OTHER ADVERSE REACTIONS: THROMBOCYTOPENIA: Platelet counts 25,000 to less than 50,000/mcL: Consider withholding this drug and/or reducing the dose. Platelet count less than 25,000/mcL: Withhold this drug until platelet count improves to Grade 3 or less; consider resuming at a reduced dose. INFUSION-RELATED REACTIONS: GRADE 2 or 3: Interrupt infusion and provide supportive care; when symptoms resolve, resume infusion rate at 50% of the previous rate. GRADE 4: Permanently discontinue therapy and provide emergency care. OTHER ADVERSE REACTIONS: GRADE 3: Withhold therapy until improvement to Grade 1 or less; consider resuming at a reduced dose. GRADE 4: Consider permanent discontinuation of therapy; if continuing therapy, withhold this drug until improvement to Grade 1 or less and resume at a reduced dose. Side Effects The Most Common nausea constipation diarrhea loss of appetite joint or back pain tiredness unusual bleeding or bruising shortness of breath, chest pain, cough More common Black, tarry stools bleeding gums blood in urine or stools blurred vision or any other change in vision body aches or pain change in color vision chest pain or tightness chills confusion constipation cough decreased frequency or amount of urine depression difficulty seeing at night difficulty with swallowing dizziness dry eye dry mouth ear congestion eye redness, irritation, or pain fainting fast heartbeat Rare fever headache incoherent speech increased sensitivity of the eyes to sunlight increased thirst increased urination lightheadedness or faintness loss of appetite loss of voice low blood pressure or pulse lower back or side pain metallic taste muscle weakness nausea pinpoint red spots on the skin pounding in the ears rapid, shallow breathing runny or stuffy nose skin rash, itching, or hives sneezing sore throat stomach pain swelling in the face, hands, or lower legs trouble breathing unconsciousness unusual bleeding or bruising unusual tiredness or weakness vomiting weight gain or loss Drug Interaction DRUG INTERACTION Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Belantamab mafodotin. Abemaciclib The serum concentration of Abemaciclib can be increased when it is combined with Belantamab mafodotin. Abrocitinib The serum concentration of Belantamab mafodotin can be increased when it is combined with Abrocitinib. Acetylcysteine The excretion of Belantamab mafodotin can be decreased when combined with Acetylcysteine. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Belantamab mafodotin. Aducanumab The risk or severity of adverse effects can be increased when Aducanumab is combined with Belantamab mafodotin. Afatinib The serum concentration of Belantamab mafodotin can be increased when it is combined with Afatinib. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Belantamab mafodotin. Alirocumab The risk or severity of adverse effects can be increased when Alirocumab is combined with Belantamab mafodotin. Ambrisentan The serum concentration of Belantamab mafodotin can be increased when it is combined with Ambrisentan. Aminohippuric acid The excretion of Belantamab mafodotin can be decreased when combined with Aminohippuric acid. Amiodarone The serum concentration of Belantamab mafodotin can be increased when it is combined with Amiodarone. Amivantamab The risk or severity of adverse effects can be increased when Belantamab mafodotin is combined with Amivantamab. Amprenavir The excretion of Belantamab mafodotin can be decreased when combined with Amprenavir. Anifrolumab The risk or severity of adverse effects can be increased when Anifrolumab is combined with Belantamab mafodotin. Ansuvimab The risk or severity of adverse effects can be increased when Belantamab mafodotin is combined with Ansuvimab. Anthrax immune globulin The risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Belantamab mafodotin. Antilymphocyte immunoglobulin The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Belantamab mafodotin. Antithymocyte immunoglobulin The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Belantamab mafodotin. Apalutamide The serum concentration of Belantamab mafodotin can be decreased when it is combined with Apalutamide. Apixaban The serum concentration of Belantamab mafodotin can be increased when it is combined with Apixaban. Arsenic trioxide The serum concentration of Belantamab mafodotin can be increased when it is combined with Arsenic trioxide. Asciminib The serum concentration of Belantamab mafodotin can be increased when it is combined with Asciminib. Asfotase alfa The risk or severity of adverse effects can be increased when Asfotase alfa is combined with Belantamab mafodotin. Astemizole Astemizole may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Asunaprevir The serum concentration of Belantamab mafodotin can be increased when it is combined with Asunaprevir. Ataluren The excretion of Belantamab mafodotin can be decreased when combined with Ataluren. Atazanavir Atazanavir may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Atenolol Atenolol may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Atezolizumab The risk or severity of adverse effects can be increased when Atezolizumab is combined with Belantamab mafodotin. Atoltivimab The risk or severity of adverse effects can be increased when Belantamab mafodotin is combined with Atoltivimab. Atorvastatin Atorvastatin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Atropine Atropine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Avanafil The serum concentration of Belantamab mafodotin can be increased when it is combined with Avanafil. Avatrombopag The serum concentration of Belantamab mafodotin can be increased when it is combined with Avatrombopag. Avelumab The risk or severity of adverse effects can be increased when Avelumab is combined with Belantamab mafodotin. Axitinib The serum concentration of Axitinib can be increased when it is combined with Belantamab mafodotin. Bamlanivimab The risk or severity of adverse effects can be increased when Bamlanivimab is combined with Belantamab mafodotin. Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Belantamab mafodotin. Bebtelovimab The risk or severity of adverse effects can be increased when Belantamab mafodotin is combined with Bebtelovimab. Beclomethasone dipropionate The excretion of Belantamab mafodotin can be decreased when combined with Beclomethasone dipropionate. Belimumab The risk or severity of adverse effects can be increased when Belimumab is combined with Belantamab mafodotin. Belinostat The serum concentration of Belantamab mafodotin can be increased when it is combined with Belinostat. Belumosudil The serum concentration of Belantamab mafodotin can be increased when it is combined with Belumosudil. Bempedoic acid The excretion of Belantamab mafodotin can be decreased when combined with Bempedoic acid. Bendamustine The serum concentration of Bendamustine can be increased when it is combined with Belantamab mafodotin. Benralizumab The risk or severity of adverse effects can be increased when Benralizumab is combined with Belantamab mafodotin. Berotralstat The serum concentration of Berotralstat can be increased when it is combined with Belantamab mafodotin. Besilesomab The risk or severity of adverse effects can be increased when Besilesomab is combined with Belantamab mafodotin. Betrixaban The serum concentration of Belantamab mafodotin can be increased when it is combined with Betrixaban. Bevacizumab The risk or severity of adverse effects can be increased when Bevacizumab is combined with Belantamab mafodotin. Bezafibrate The excretion of Belantamab mafodotin can be decreased when combined with Bezafibrate. Bezlotoxumab The risk or severity of adverse effects can be increased when Bezlotoxumab is combined with Belantamab mafodotin. Bimekizumab The risk or severity of adverse effects can be increased when Bimekizumab is combined with Belantamab mafodotin. Binimetinib The serum concentration of Binimetinib can be increased when it is combined with Belantamab mafodotin. Bisoprolol The serum concentration of Belantamab mafodotin can be increased when it is combined with Bisoprolol. Blinatumomab The risk or severity of adverse effects can be increased when Blinatumomab is combined with Belantamab mafodotin. Bortezomib The serum concentration of Bortezomib can be increased when it is combined with Belantamab mafodotin. Bosentan Bosentan may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Bosutinib The serum concentration of Bosutinib can be increased when it is combined with Belantamab mafodotin. Brentuximab vedotin The serum concentration of Brentuximab vedotin can be increased when it is combined with Belantamab mafodotin. Brodalumab The risk or severity of adverse effects can be increased when Brodalumab is combined with Belantamab mafodotin. Brolucizumab The risk or severity of adverse effects can be increased when Brolucizumab is combined with Belantamab mafodotin. Budesonide Budesonide may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Burosumab The risk or severity of adverse effects can be increased when Burosumab is combined with Belantamab mafodotin. Cabazitaxel The serum concentration of Cabazitaxel can be increased when it is combined with Belantamab mafodotin. Cabergoline The serum concentration of Cabergoline can be increased when it is combined with Belantamab mafodotin. Canagliflozin The serum concentration of Belantamab mafodotin can be increased when it is combined with Canagliflozin. Canakinumab The risk or severity of adverse effects can be increased when Canakinumab is combined with Belantamab mafodotin. Caplacizumab The risk or severity of adverse effects can be increased when Caplacizumab is combined with Belantamab mafodotin. Capmatinib The serum concentration of Belantamab mafodotin can be increased when it is combined with Capmatinib. Capromab pendetide The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Belantamab mafodotin. Carfilzomib The serum concentration of Belantamab mafodotin can be increased when it is combined with Carfilzomib. Carvedilol The serum concentration of Belantamab mafodotin can be increased when it is combined with Carvedilol. Casirivimab The risk or severity of adverse effects can be increased when Belantamab mafodotin is combined with Casirivimab. Caspofungin The excretion of Belantamab mafodotin can be decreased when combined with Caspofungin. Catumaxomab The risk or severity of adverse effects can be increased when Catumaxomab is combined with Belantamab mafodotin. Cefaclor Cefaclor may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Celecoxib Celecoxib may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Cemiplimab The risk or severity of adverse effects can be increased when Cemiplimab is combined with Belantamab mafodotin. Ceritinib The serum concentration of Ceritinib can be increased when it is combined with Belantamab mafodotin. Cerivastatin Cerivastatin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Certolizumab pegol The risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Belantamab mafodotin. Cetuximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Belantamab mafodotin. Chlorpromazine Chlorpromazine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Cholecystokinin The excretion of Belantamab mafodotin can be decreased when combined with Cholecystokinin. Cholic Acid Cholic Acid may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Cilgavimab The risk or severity of adverse effects can be increased when Belantamab mafodotin is combined with Cilgavimab. Cimetidine Cimetidine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Clarithromycin The serum concentration of Belantamab mafodotin can be increased when it is combined with Clarithromycin. Clobazam The serum concentration of Belantamab mafodotin can be increased when it is combined with Clobazam. Clofazimine The serum concentration of Belantamab mafodotin can be increased when it is combined with Clofazimine. Clomifene The serum concentration of Belantamab mafodotin can be increased when it is combined with Clomifene. Cobicistat The serum concentration of Belantamab mafodotin can be increased when it is combined with Cobicistat. Cobimetinib The serum concentration of Cobimetinib can be increased when it is combined with Belantamab mafodotin. Colchicine The serum concentration of Belantamab mafodotin can be increased when it is combined with Colchicine. Conivaptan The serum concentration of Belantamab mafodotin can be increased when it is combined with Conivaptan. Conjugated estrogens Conjugated estrogens may increase the thrombogenic activities of Belantamab mafodotin. Copanlisib The serum concentration of Copanlisib can be increased when it is combined with Belantamab mafodotin. Crizotinib The serum concentration of Belantamab mafodotin can be increased when it is combined with Crizotinib. Curcumin The serum concentration of Belantamab mafodotin can be increased when it is combined with Curcumin. Cyclosporine Cyclosporine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Dabigatran etexilate The serum concentration of Belantamab mafodotin can be increased when it is combined with Dabigatran etexilate. Dabrafenib The serum concentration of Dabrafenib can be increased when it is combined with Belantamab mafodotin. Daclatasvir The serum concentration of Belantamab mafodotin can be increased when it is combined with Daclatasvir. Dacomitinib The serum concentration of Belantamab mafodotin can be increased when it is combined with Dacomitinib. Dactinomycin The serum concentration of Dactinomycin can be increased when it is combined with Belantamab mafodotin. Daptomycin The serum concentration of Belantamab mafodotin can be increased when it is combined with Daptomycin. Daratumumab The risk or severity of adverse effects can be increased when Daratumumab is combined with Belantamab mafodotin. Darolutamide The serum concentration of Belantamab mafodotin can be increased when it is combined with Darolutamide. Darunavir The serum concentration of Belantamab mafodotin can be increased when it is combined with Darunavir. Dasabuvir The serum concentration of Belantamab mafodotin can be increased when it is combined with Dasabuvir. Dasatinib The serum concentration of Dasatinib can be increased when it is combined with Belantamab mafodotin. Daunorubicin Daunorubicin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Belantamab mafodotin. Deoxycholic acid Deoxycholic acid may increase the excretion rate of Belantamab mafodotin which could result in a lower serum level and potentially a reduction in efficacy. Dexamethasone Dexamethasone may increase the excretion rate of Belantamab mafodotin which could result in a lower serum level and potentially a reduction in efficacy. Dexamethasone acetate Dexamethasone acetate may increase the excretion rate of Belantamab mafodotin which could result in a lower serum level and potentially a reduction in efficacy. Diclofenac Diclofenac may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Dienestrol Dienestrol may increase the thrombogenic activities of Belantamab mafodotin. Diethylstilbestrol Diethylstilbestrol may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Digitoxin The serum concentration of Digitoxin can be increased when it is combined with Belantamab mafodotin. Digoxin Digoxin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Digoxin Immune The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Belantamab mafodotin. Dihydroergocristine Dihydroergocristine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Dinutuximab The risk or severity of adverse effects can be increased when Dinutuximab is combined with Belantamab mafodotin. Diosmin The serum concentration of Belantamab mafodotin can be increased when it is combined with Diosmin. Dipyridamole Dipyridamole may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Disulfiram Disulfiram may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Dolutegravir The serum concentration of Belantamab mafodotin can be increased when it is combined with Dolutegravir. Dostarlimab The risk or severity of adverse effects can be increased when Dostarlimab is combined with Belantamab mafodotin. Doxorubicin Doxorubicin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Dronedarone The serum concentration of Belantamab mafodotin can be increased when it is combined with Dronedarone. Dulaglutide The risk or severity of adverse effects can be increased when Dulaglutide is combined with Belantamab mafodotin. Dupilumab The risk or severity of adverse effects can be increased when Dupilumab is combined with Belantamab mafodotin. Durvalumab The risk or severity of adverse effects can be increased when Durvalumab is combined with Belantamab mafodotin. Duvelisib The serum concentration of Belantamab mafodotin can be increased when it is combined with Duvelisib. Ebola Zaire vaccine The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Belantamab mafodotin. Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Belantamab mafodotin. Edoxaban The serum concentration of Belantamab mafodotin can be increased when it is combined with Edoxaban. Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Belantamab mafodotin. Efavirenz Efavirenz may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Eflapegrastim The risk or severity of adverse effects can be increased when Eflapegrastim is combined with Belantamab mafodotin. Eftrenonacog alfa The risk or severity of adverse effects can be increased when Eftrenonacog alfa is combined with Belantamab mafodotin. Elagolix The serum concentration of Belantamab mafodotin can be increased when it is combined with Elagolix. Elbasvir The serum concentration of Belantamab mafodotin can be increased when it is combined with Elbasvir. Elexacaftor The excretion of Belantamab mafodotin can be decreased when combined with Elexacaftor. Eliglustat The serum concentration of Belantamab mafodotin can be increased when it is combined with Eliglustat. Elotuzumab The risk or severity of adverse effects can be increased when Elotuzumab is combined with Belantamab mafodotin. Eltrombopag The excretion of Belantamab mafodotin can be decreased when combined with Eltrombopag. Eluxadoline The excretion of Belantamab mafodotin can be decreased when combined with Eluxadoline. Emapalumab The risk or severity of adverse effects can be increased when Emapalumab is combined with Belantamab mafodotin. Emicizumab The risk or severity of adverse effects can be increased when Emicizumab is combined with Belantamab mafodotin. Enasidenib The serum concentration of Belantamab mafodotin can be increased when it is combined with Enasidenib. Enfortumab vedotin The serum concentration of Belantamab mafodotin can be increased when it is combined with Enfortumab vedotin. Entrectinib The serum concentration of Belantamab mafodotin can be increased when it is combined with Entrectinib. Eptinezumab The risk or severity of adverse effects can be increased when Eptinezumab is combined with Belantamab mafodotin. Erdafitinib The serum concentration of Belantamab mafodotin can be increased when it is combined with Erdafitinib. Erenumab The risk or severity of adverse effects can be increased when Erenumab is combined with Belantamab mafodotin. Ertugliflozin The serum concentration of Belantamab mafodotin can be increased when it is combined with Ertugliflozin. Erythromycin Erythromycin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Esterified estrogens Esterified estrogens may increase the thrombogenic activities of Belantamab mafodotin. Estetrol Estetrol may increase the thrombogenic activities of Belantamab mafodotin. Estradiol Estradiol may increase the thrombogenic activities of Belantamab mafodotin. Estradiol acetate Estradiol acetate may increase the thrombogenic activities of Belantamab mafodotin. Estradiol benzoate Estradiol benzoate may increase the thrombogenic activities of Belantamab mafodotin. Estradiol cypionate Estradiol cypionate may increase the thrombogenic activities of Belantamab mafodotin. Estradiol dienanthate The excretion of Belantamab mafodotin can be decreased when combined with Estradiol dienanthate. Estradiol valerate Estradiol valerate may increase the thrombogenic activities of Belantamab mafodotin. Estriol Estriol may increase the thrombogenic activities of Belantamab mafodotin. Estrone Estrone may increase the thrombogenic activities of Belantamab mafodotin. Estrone sulfate Estrone sulfate may increase the thrombogenic activities of Belantamab mafodotin. Ethinylestradiol Ethinylestradiol may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Etoposide The serum concentration of Etoposide can be increased when it is combined with Belantamab mafodotin. Everolimus The serum concentration of Belantamab mafodotin can be increased when it is combined with Everolimus. Evolocumab The risk or severity of adverse effects can be increased when Evolocumab is combined with Belantamab mafodotin. Ezetimibe Ezetimibe may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Fanolesomab The risk or severity of adverse effects can be increased when Fanolesomab is combined with Belantamab mafodotin. Favipiravir The serum concentration of Belantamab mafodotin can be increased when it is combined with Favipiravir. Fedratinib The serum concentration of Belantamab mafodotin can be increased when it is combined with Fedratinib. Felodipine Felodipine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Fenofibrate Fenofibrate may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Fexofenadine The serum concentration of Belantamab mafodotin can be increased when it is combined with Fexofenadine. Filgotinib The serum concentration of Belantamab mafodotin can be increased when it is combined with Filgotinib. Flibanserin The serum concentration of Belantamab mafodotin can be increased when it is combined with Flibanserin. Flucloxacillin Flucloxacillin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Fluconazole The serum concentration of Belantamab mafodotin can be increased when it is combined with Fluconazole. Fluorescein Fluorescein may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Fluticasone The excretion of Belantamab mafodotin can be decreased when combined with Fluticasone. Fluticasone furoate The excretion of Belantamab mafodotin can be decreased when combined with Fluticasone furoate. Fluticasone propionate The excretion of Belantamab mafodotin can be decreased when combined with Fluticasone propionate. Fluvastatin The excretion of Belantamab mafodotin can be decreased when combined with Fluvastatin. Fluvoxamine Fluvoxamine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Fostemsavir The serum concentration of Belantamab mafodotin can be increased when it is combined with Fostemsavir. Fremanezumab The risk or severity of adverse effects can be increased when Fremanezumab is combined with Belantamab mafodotin. Fusidic acid Fusidic acid may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Futibatinib The serum concentration of Belantamab mafodotin can be increased when it is combined with Futibatinib. Galcanezumab The risk or severity of adverse effects can be increased when Galcanezumab is combined with Belantamab mafodotin. Gemcitabine The serum concentration of Gemcitabine can be increased when it is combined with Belantamab mafodotin. Gemfibrozil The excretion of Belantamab mafodotin can be decreased when combined with Gemfibrozil. Gilteritinib The serum concentration of Belantamab mafodotin can be increased when it is combined with Gilteritinib. Glasdegib The serum concentration of Belantamab mafodotin can be increased when it is combined with Glasdegib. Glecaprevir The serum concentration of Belantamab mafodotin can be increased when it is combined with Glecaprevir. Glimepiride Glimepiride may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Glipizide Glipizide may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Glyburide Glyburide may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Glycyrrhizic acid Glycyrrhizic acid may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Golimumab The risk or severity of adverse effects can be increased when Golimumab is combined with Belantamab mafodotin. Grazoprevir The serum concentration of Belantamab mafodotin can be increased when it is combined with Grazoprevir. Guselkumab The risk or severity of adverse effects can be increased when Guselkumab is combined with Belantamab mafodotin. Hepatitis B immune The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Belantamab mafodotin. cytomegalovirus immune The risk or severity of adverse effects can be increased when Human cytomegalovirus immune globulin is combined with Belantamab mafodotin. Human immunoglobulin G The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Belantamab mafodotin. Human Rho(D) The risk or severity of adverse effects can be increased when Human Rho(D) immune globulin is combined with Belantamab mafodotin. Human varicella-zoster The risk or severity of adverse effects can be increased when Human varicella-zoster immune globulin is combined with Belantamab mafodotin. Ibalizumab The risk or severity of adverse effects can be increased when Ibalizumab is combined with Belantamab mafodotin. Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Belantamab mafodotin. Idarucizumab The risk or severity of adverse effects can be increased when Idarucizumab is combined with Belantamab mafodotin. Idelalisib The serum concentration of Belantamab mafodotin can be increased when it is combined with Idelalisib. Imatinib Imatinib may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Imdevimab The risk or severity of adverse effects can be increased when Belantamab mafodotin is combined with Imdevimab. Imipramine The serum concentration of Imipramine can be increased when it is combined with Belantamab mafodotin. Imlifidase The therapeutic efficacy of Belantamab mafodotin can be decreased when used in combination with Imlifidase. Indacaterol The serum concentration of Belantamab mafodotin can be increased when it is combined with Indacaterol. Indinavir Indinavir may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Indocyanine green acid Indocyanine green acid form may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Indomethacin Indomethacin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Inebilizumab The risk or severity of adverse effects can be increased when Inebilizumab is combined with Belantamab mafodotin. Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Belantamab mafodotin. Inotuzumab ozogamicin The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Belantamab mafodotin. Ipilimumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Belantamab mafodotin. Irinotecan The excretion of Belantamab mafodotin can be decreased when combined with Irinotecan. Isatuximab The risk or severity of adverse effects can be increased when Isatuximab is combined with Belantamab mafodotin. Isavuconazole The serum concentration of Belantamab mafodotin can be increased when it is combined with Isavuconazole. Isavuconazonium The serum concentration of Belantamab mafodotin can be increased when it is combined with Isavuconazonium. Isradipine Isradipine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Istradefylline The serum concentration of Belantamab mafodotin can be increased when it is combined with Istradefylline. Itraconazole The serum concentration of Belantamab mafodotin can be increased when it is combined with Itraconazole. Ivacaftor The serum concentration of Belantamab mafodotin can be increased when it is combined with Ivacaftor. Ivermectin The excretion of Belantamab mafodotin can be decreased when combined with Ivermectin. Ixabepilone The serum concentration of Belantamab mafodotin can be increased when it is combined with Ixabepilone. Ixekizumab The risk or severity of adverse effects can be increased when Ixekizumab is combined with Belantamab mafodotin. Ketoconazole Ketoconazole may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Lanadelumab The risk or severity of adverse effects can be increased when Lanadelumab is combined with Belantamab mafodotin. Lapatinib The serum concentration of Belantamab mafodotin can be increased when it is combined with Lapatinib. Larotrectinib The serum concentration of Belantamab mafodotin can be increased when it is combined with Larotrectinib. Lasmiditan The serum concentration of Belantamab mafodotin can be increased when it is combined with Lasmiditan. Ledipasvir The serum concentration of Belantamab mafodotin can be increased when it is combined with Ledipasvir. Lefamulin The serum concentration of Belantamab mafodotin can be increased when it is combined with Lefamulin. Lemborexant The serum concentration of Belantamab mafodotin can be increased when it is combined with Lemborexant. Lenvatinib Lenvatinib may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Letermovir Letermovir may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Levocarnitine The excretion of Belantamab mafodotin can be decreased when combined with Levocarnitine. Levoketoconazole The serum concentration of Belantamab mafodotin can be increased when it is combined with Levoketoconazole. Levothyroxine The excretion of Belantamab mafodotin can be decreased when combined with Levothyroxine. Linagliptin The serum concentration of Belantamab mafodotin can be increased when it is combined with Linagliptin. Lomitapide The serum concentration of Belantamab mafodotin can be increased when it is combined with Lomitapide. Lonafarnib The serum concentration of Belantamab mafodotin can be increased when it is combined with Lonafarnib. Loncastuximab tesirine The serum concentration of Loncastuximab tesirine can be increased when it is combined with Belantamab mafodotin. Loperamide The serum concentration of Belantamab mafodotin can be increased when it is combined with Loperamide. Lopinavir The serum concentration of Belantamab mafodotin can be increased when it is combined with Lopinavir. Loratadine Loratadine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Losartan Losartan may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Lovastatin Lovastatin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Loxapine The serum concentration of Belantamab mafodotin can be increased when it is combined with Loxapine. Lumacaftor The serum concentration of Belantamab mafodotin can be decreased when it is combined with Lumacaftor. Lusutrombopag The serum concentration of Belantamab mafodotin can be increased when it is combined with Lusutrombopag. Maftivimab The risk or severity of adverse effects can be increased when Belantamab mafodotin is combined with Maftivimab. Mannitol The serum concentration of Belantamab mafodotin can be increased when it is combined with Mannitol. Margetuximab The risk or severity of adverse effects can be increased when Margetuximab is combined with Belantamab mafodotin. Maribavir The serum concentration of Belantamab mafodotin can be increased when it is combined with Maribavir. Mefloquine The serum concentration of Belantamab mafodotin can be increased when it is combined with Mefloquine. Mepolizumab The risk or severity of adverse effects can be increased when Mepolizumab is combined with Belantamab mafodotin. Mestranol Mestranol may increase the thrombogenic activities of Belantamab mafodotin. Methylene blue The serum concentration of Belantamab mafodotin can be increased when it is combined with Methylene blue. Mifepristone The serum concentration of Belantamab mafodotin can be increased when it is combined with Mifepristone. Mirabegron The serum concentration of Belantamab mafodotin can be increased when it is combined with Mirabegron. Mitapivat The serum concentration of Belantamab mafodotin can be increased when it is combined with Mitapivat. Mogamulizumab The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Belantamab mafodotin. Morphine The serum concentration of Belantamab mafodotin can be increased when it is combined with Morphine. Mosunetuzumab The risk or severity of adverse effects can be increased when Mosunetuzumab is combined with Belantamab mafodotin. Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Belantamab mafodotin. Naproxen Naproxen may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Natalizumab The risk or severity of adverse effects can be increased when Natalizumab is combined with Belantamab mafodotin. Necitumumab The risk or severity of adverse effects can be increased when Necitumumab is combined with Belantamab mafodotin. Nefazodone Nefazodone may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Nelfinavir Nelfinavir may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Neratinib The serum concentration of Belantamab mafodotin can be increased when it is combined with Neratinib. Netupitant The serum concentration of Belantamab mafodotin can be increased when it is combined with Netupitant. Nicardipine Nicardipine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Nifedipine Nifedipine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Nilotinib The serum concentration of Belantamab mafodotin can be increased when it is combined with Nilotinib. Nintedanib The serum concentration of Belantamab mafodotin can be increased when it is combined with Nintedanib. Nitrendipine Nitrendipine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Nitrofurantoin Nitrofurantoin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Nivolumab The risk or severity of adverse effects can be increased when Nivolumab is combined with Belantamab mafodotin. Norgestimate The serum concentration of Belantamab mafodotin can be increased when it is combined with Norgestimate. Nortriptyline The serum concentration of Nortriptyline can be increased when it is combined with Belantamab mafodotin. Novobiocin The excretion of Belantamab mafodotin can be decreased when combined with Novobiocin. Nystatin The excretion of Belantamab mafodotin can be decreased when combined with Nystatin. Obiltoxaximab The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Belantamab mafodotin. Obinutuzumab The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Belantamab mafodotin. Ocrelizumab The risk or severity of adverse effects can be increased when Ocrelizumab is combined with Belantamab mafodotin. Odesivimab The risk or severity of adverse effects can be increased when Belantamab mafodotin is combined with Odesivimab. Ofatumumab The risk or severity of adverse effects can be increased when Ofatumumab is combined with Belantamab mafodotin. Ofloxacin Ofloxacin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Olaratumab The risk or severity of adverse effects can be increased when Olaratumab is combined with Belantamab mafodotin. Olmesartan Olmesartan may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Omadacycline The serum concentration of Belantamab mafodotin can be increased when it is combined with Omadacycline. Omalizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Belantamab mafodotin. Ombitasvir The serum concentration of Belantamab mafodotin can be increased when it is combined with Ombitasvir. Osimertinib The serum concentration of Osimertinib can be increased when it is combined with Belantamab mafodotin. Ouabain The excretion of Belantamab mafodotin can be decreased when combined with Ouabain. Paclitaxel Paclitaxel may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Pacritinib The serum concentration of Belantamab mafodotin can be increased when it is combined with Pacritinib. Palbociclib The serum concentration of Belantamab mafodotin can be increased when it is combined with Palbociclib. Paliperidone The serum concentration of Belantamab mafodotin can be increased when it is combined with Paliperidone. Palivizumab The risk or severity of adverse effects can be increased when Palivizumab is combined with Belantamab mafodotin. Panitumumab The risk or severity of adverse effects can be increased when Panitumumab is combined with Belantamab mafodotin. Panobinostat The serum concentration of Panobinostat can be increased when it is combined with Belantamab mafodotin. Pantoprazole The excretion of Belantamab mafodotin can be decreased when combined with Pantoprazole. Paritaprevir The serum concentration of Belantamab mafodotin can be increased when it is combined with Paritaprevir. Pazopanib The serum concentration of Pazopanib can be increased when it is combined with Belantamab mafodotin. Pembrolizumab The risk or severity of adverse effects can be increased when Pembrolizumab is combined with Belantamab mafodotin. Pertuzumab The risk or severity of adverse effects can be increased when Pertuzumab is combined with Belantamab mafodotin. Pexidartinib The excretion of Belantamab mafodotin can be decreased when combined with Pexidartinib. Phenobarbital Phenobarbital may increase the excretion rate of Belantamab mafodotin which could result in a lower serum level and potentially a reduction in efficacy. Pibrentasvir The serum concentration of Belantamab mafodotin can be increased when it is combined with Pibrentasvir. Pitavastatin Pitavastatin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Pitolisant The serum concentration of Belantamab mafodotin can be increased when it is combined with Pitolisant. Polatuzumab vedotin The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Belantamab mafodotin. Polyestradiol phosphate Polyestradiol phosphate may increase the thrombogenic activities of Belantamab mafodotin. Pomalidomide The serum concentration of Pomalidomide can be increased when it is combined with Belantamab mafodotin. Ponatinib The serum concentration of Belantamab mafodotin can be increased when it is combined with Ponatinib. Posaconazole The serum concentration of Belantamab mafodotin can be increased when it is combined with Posaconazole. Pralsetinib Pralsetinib may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Pravastatin Pravastatin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Prednisolone phosphate The serum concentration of Belantamab mafodotin can be increased when it is combined with Prednisolone phosphate. Progesterone Progesterone may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Propafenone The serum concentration of Belantamab mafodotin can be increased when it is combined with Propafenone. Quinestrol Quinestrol may increase the thrombogenic activities of Belantamab mafodotin. Quinidine Quinidine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Quinine The serum concentration of Belantamab mafodotin can be increased when it is combined with Quinine. Ramucirumab The risk or severity of adverse effects can be increased when Ramucirumab is combined with Belantamab mafodotin. Ranibizumab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Belantamab mafodotin. Ranolazine The serum concentration of Belantamab mafodotin can be increased when it is combined with Ranolazine. Ravulizumab The risk or severity of adverse effects can be increased when Ravulizumab is combined with Belantamab mafodotin. Raxibacumab The risk or severity of adverse effects can be increased when Raxibacumab is combined with Belantamab mafodotin. Regorafenib The serum concentration of Belantamab mafodotin can be increased when it is combined with Regorafenib. Relugolix The serum concentration of Belantamab mafodotin can be increased when it is combined with Relugolix. Remdesivir The excretion of Belantamab mafodotin can be decreased when combined with Remdesivir. Repaglinide Repaglinide may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Reserpine Reserpine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Reslizumab The risk or severity of adverse effects can be increased when Reslizumab is combined with Belantamab mafodotin. Revefenacin The serum concentration of Belantamab mafodotin can be increased when it is combined with Revefenacin. Rifampicin Rifampicin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Rifamycin The serum concentration of Belantamab mafodotin can be increased when it is combined with Rifamycin. Rilpivirine The excretion of Belantamab mafodotin can be decreased when combined with Rilpivirine. Rimegepant The serum concentration of Belantamab mafodotin can be increased when it is combined with Rimegepant. Riociguat The serum concentration of Belantamab mafodotin can be increased when it is combined with Riociguat. Ripretinib The serum concentration of Belantamab mafodotin can be increased when it is combined with Ripretinib. Risankizumab The risk or severity of adverse effects can be increased when Risankizumab is combined with Belantamab mafodotin. Ritonavir The serum concentration of Belantamab mafodotin can be increased when it is combined with Ritonavir. Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Belantamab mafodotin. Rivaroxaban The serum concentration of Belantamab mafodotin can be increased when it is combined with Rivaroxaban. Rolapitant The serum concentration of Belantamab mafodotin can be increased when it is combined with Rolapitant. Romidepsin The serum concentration of Romidepsin can be increased when it is combined with Belantamab mafodotin. Romosozumab The risk or severity of adverse effects can be increased when Romosozumab is combined with Belantamab mafodotin. Rosiglitazone Rosiglitazone may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Rosuvastatin Rosuvastatin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Roxadustat The serum concentration of Belantamab mafodotin can be increased when it is combined with Roxadustat. Roxithromycin The excretion of Belantamab mafodotin can be decreased when combined with Roxithromycin. Sacituzumab govitecan The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Belantamab mafodotin. Sacubitril The excretion of Belantamab mafodotin can be decreased when combined with Sacubitril. Sapropterin The serum concentration of Belantamab mafodotin can be increased when it is combined with Sapropterin. Saquinavir The serum concentration of Belantamab mafodotin can be increased when it is combined with Saquinavir. Sarecycline The serum concentration of Belantamab mafodotin can be increased when it is combined with Sarecycline. Sarilumab The risk or severity of adverse effects can be increased when Sarilumab is combined with Belantamab mafodotin. Secukinumab The risk or severity of adverse effects can be increased when Secukinumab is combined with Belantamab mafodotin. Selexipag The serum concentration of Belantamab mafodotin can be increased when it is combined with Selexipag. Selinexor The excretion of Belantamab mafodotin can be decreased when combined with Selinexor. Selumetinib The serum concentration of Belantamab mafodotin can be increased when it is combined with Selumetinib. Sildenafil The serum concentration of Belantamab mafodotin can be increased when it is combined with Sildenafil. Silodosin The serum concentration of Belantamab mafodotin can be increased when it is combined with Silodosin. Siltuximab The risk or severity of adverse effects can be increased when Siltuximab is combined with Belantamab mafodotin. Simeprevir Simeprevir may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Simvastatin The serum concentration of Belantamab mafodotin can be increased when it is combined with Simvastatin. Sirolimus The serum concentration of Sirolimus can be increased when it is combined with Belantamab mafodotin. Sitagliptin The serum concentration of Belantamab mafodotin can be increased when it is combined with Sitagliptin. Sofosbuvir The serum concentration of Belantamab mafodotin can be increased when it is combined with Sofosbuvir. Sorafenib The serum concentration of Belantamab mafodotin can be increased when it is combined with Sorafenib. Sotagliflozin The serum concentration of Belantamab mafodotin can be increased when it is combined with Sotagliflozin. Sotorasib The serum concentration of Belantamab mafodotin can be increased when it is combined with Sotorasib. Sotrovimab The risk or severity of adverse effects can be increased when Belantamab mafodotin is combined with Sotrovimab. Spesolimab The risk or severity of adverse effects can be increased when Spesolimab is combined with Belantamab mafodotin. Spironolactone Spironolactone may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Stiripentol The excretion of Belantamab mafodotin can be decreased when combined with Stiripentol. Sulesomab The risk or severity of adverse effects can be increased when Sulesomab is combined with Belantamab mafodotin. Sulfamethoxazole Sulfamethoxazole may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Sulfasalazine The excretion of Belantamab mafodotin can be decreased when combined with Sulfasalazine. Sulfinpyrazone Sulfinpyrazone may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Sutimlimab The risk or severity of adverse effects can be increased when Sutimlimab is combined with Belantamab mafodotin. Suvorexant The serum concentration of Belantamab mafodotin can be increased when it is combined with Suvorexant.  Estrogens, A Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Belantamab mafodotin.  Estrogens, B Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Belantamab mafodotin. Tacrolimus The serum concentration of Belantamab mafodotin can be increased when it is combined with Tacrolimus. Tafasitamab The risk or severity of adverse effects can be increased when Tafasitamab is combined with Belantamab mafodotin. Talazoparib The serum concentration of Talazoparib can be increased when it is combined with Belantamab mafodotin. Tamoxifen Tamoxifen may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Taurocholic acid Taurocholic acid may increase the excretion rate of Belantamab mafodotin which could result in a lower serum level and potentially a reduction in efficacy. Tazemetostat The serum concentration of Belantamab mafodotin can be increased when it is combined with Tazemetostat. Technetium The serum concentration of Belantamab mafodotin can be increased when it is combined with Technetium Tc-99m sestamibi. Tegaserod The serum concentration of Belantamab mafodotin can be increased when it is combined with Tegaserod. Telaprevir The serum concentration of Belantamab mafodotin can be increased when it is combined with Telaprevir. Telithromycin The excretion of Belantamab mafodotin can be decreased when combined with Telithromycin. Telmisartan Telmisartan may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Temsirolimus The serum concentration of Belantamab mafodotin can be increased when it is combined with Temsirolimus. Tenofovir disoproxil The serum concentration of Belantamab mafodotin can be increased when it is combined with Tenofovir disoproxil. Tepotinib The serum concentration of Belantamab mafodotin can be increased when it is combined with Tepotinib. Terfenadine Terfenadine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Teriflunomide The excretion of Belantamab mafodotin can be decreased when combined with Teriflunomide. Tetanus The risk or severity of adverse effects can be increased when Tetanus immune globulin, human is combined with Belantamab mafodotin. Tezacaftor The serum concentration of Belantamab mafodotin can be increased when it is combined with Tezacaftor. Tezepelumab The risk or severity of adverse effects can be increased when Tezepelumab is combined with Belantamab mafodotin. Tibolone Tibolone may increase the thrombogenic activities of Belantamab mafodotin. Ticagrelor The serum concentration of Belantamab mafodotin can be increased when it is combined with Ticagrelor. Tildrakizumab The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Belantamab mafodotin. Tinidazole Tinidazole may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Tipranavir Tipranavir may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Tisotumab vedotin The risk or severity of adverse effects can be increased when Belantamab mafodotin is combined with Tisotumab vedotin. Tivozanib The serum concentration of Belantamab mafodotin can be increased when it is combined with Tivozanib. Tixagevimab The risk or severity of adverse effects can be increased when Belantamab mafodotin is combined with Tixagevimab. Tocilizumab The risk or severity of adverse effects can be increased when Tocilizumab is combined with Belantamab mafodotin. Tolvaptan The serum concentration of Tolvaptan can be increased when it is combined with Belantamab mafodotin. Topotecan The serum concentration of Topotecan can be increased when it is combined with Belantamab mafodotin. Toremifene The serum concentration of Belantamab mafodotin can be increased when it is combined with Toremifene. Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Belantamab mafodotin. Tralokinumab The risk or severity of adverse effects can be increased when Tralokinumab is combined with Belantamab mafodotin. Trastuzumab The risk or severity of adverse effects can be increased when Trastuzumab is combined with Belantamab mafodotin. Trastuzumab deruxtecan The risk or severity of adverse effects can be increased when Trastuzumab deruxtecan is combined with Belantamab mafodotin. Trastuzumab emtansine The serum concentration of Trastuzumab emtansine can be increased when it is combined with Belantamab mafodotin. Tremelimumab The risk or severity of adverse effects can be increased when Tremelimumab is combined with Belantamab mafodotin. Trilaciclib The serum concentration of Belantamab mafodotin can be increased when it is combined with Trilaciclib. Trimipramine The serum concentration of Trimipramine can be increased when it is combined with Belantamab mafodotin. Troglitazone Troglitazone may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Tucatinib Tucatinib may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Ubrogepant The serum concentration of Belantamab mafodotin can be increased when it is combined with Ubrogepant. Umbralisib The serum concentration of Belantamab mafodotin can be increased when it is combined with Umbralisib. Umeclidinium The serum concentration of Belantamab mafodotin can be increased when it is combined with Umeclidinium. Ursodeoxycholic acid Ursodeoxycholic acid may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Ustekinumab The risk or severity of adverse effects can be increased when Ustekinumab is combined with Belantamab mafodotin. Valsartan The excretion of Belantamab mafodotin can be decreased when combined with Valsartan. Vandetanib The serum concentration of Belantamab mafodotin can be increased when it is combined with Vandetanib. Vardenafil The serum concentration of Belantamab mafodotin can be increased when it is combined with Vardenafil. Vedolizumab The risk or severity of adverse effects can be increased when Vedolizumab is combined with Belantamab mafodotin. Velpatasvir The serum concentration of Belantamab mafodotin can be increased when it is combined with Velpatasvir. Vemurafenib The serum concentration of Belantamab mafodotin can be increased when it is combined with Vemurafenib. Venetoclax The serum concentration of Belantamab mafodotin can be increased when it is combined with Venetoclax. Verapamil The serum concentration of Belantamab mafodotin can be increased when it is combined with Verapamil. Vinblastine Vinblastine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Vincristine Vincristine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Vinflunine The serum concentration of Vinflunine can be increased when it is combined with Belantamab mafodotin. Voclosporin The serum concentration of Belantamab mafodotin can be increased when it is combined with Voclosporin. Vorapaxar The serum concentration of Belantamab mafodotin can be increased when it is combined with Vorapaxar. Voxilaprevir The serum concentration of Belantamab mafodotin can be increased when it is combined with Voxilaprevir. Zonisamide The serum concentration of Belantamab mafodotin can be increased when it is combined with Zonisamide. Pregnancy and Lactation  US FDA pregnancy category: Not assigned. Pregnancy The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help healthcare providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out. Based on its mechanism of action, this drug can cause fetal harm when administered to a pregnant woman, because it contains a genotoxic compound (the microtubule inhibitor, MMAF) and targets actively dividing cells. Human immunoglobulin G (IgG) is known to cross the placenta; therefore, this drug has the potential to be transmitted from the mother to the developing fetus. Lactation There are no data on the presence of this drug in human milk or the effects on the breastfed child or milk production. Because of the potential for serious adverse reactions in the breastfed child, advise women not to breastfeed during therapy and for 3 months after. How should this medicine be used?

Belantamab mafodotin-blmf comes as a powder to be mixed with liquid and injected intravenously (into a vein) over 30 minutes by a doctor or nurse in a hospital or medical facility. It is usually given once every 3 weeks. The cycle may be repeated as recommended by your doctor. The length of your treatment depends on how well your body responds to the medication and any side effects that you experience. A doctor or nurse will watch you closely while…

References

Add references, clinical guidelines, textbooks, journal articles, or trusted medical sources here. You can edit this area from the RX Article Professional Blocks panel.

More from this topic
  1. Vasodilator Drugs

    Vasodilator drugs relax and widen blood vessels, increasing blood flow. A few examples include ACE inhibitors, ARBs, calcium channel blockers, and nitrates.   DefinitionVasodilators are medicines that dilate...

    June 9, 2025 • Drugs (A - Z)
  2. Methamphetamine Hydrochloride – Uses, Dosage, Side Effects, Interaction

    Methamphetamine Hydrochloride is the hydrochloride salt form of methamphetamine, an amphetamine and sympathomimetic amine with CNS stimulating properties. Methamphetamine hydrochloride acts by facilitating the release of catecholamines, particularly noradrenaline and dopamine, from...

    June 5, 2025 • Drugs (A - Z)
  3. Methamphetamine – Uses, Dosage, Side Effects, Interactions

    Methamphetamine is a member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent. It has a role as a neurotoxin, a psychotropic drug,...

    June 5, 2025 • Drugs (A - Z)
  4. Vitamin D3 – Uses, Dosage, Side Effects, Interactions

    DefinitionCholecalciferol is a steroid? hormone produced in the skin when exposed to ultraviolet light or obtained from dietary sources. The active form of cholecalciferol, 1,25-dihydroxycholecalciferol (calcitriol) plays an important role...

    March 10, 2025 • Drugs (A - Z)
  5. Imidazole – Uses, Dosage, Side Effects, Interactions

    DefinitionImidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is...

    October 20, 2023 • Drugs (A - Z)
  6. Carbimazole

    Carbimazole is a member of the class of imidazoles that is methimazole in which the nitrogen-bearing hydrogen is converted into its methoxycarbonyl derivative. A prodrug for methimazole, carbimazole is...

    October 20, 2023 • Drugs (A - Z)
  7. Methylthiouracil – Uses, Dosage, Side Effects, Interactions

    DefinitionA thiourea antithyroid agent that inhibits the synthesis of thyroid? hormone. It is used in the treatment of hyperthyroidism?. Methylthiouracil is an organosulfur compound that is used in...

    October 20, 2023 • Drugs (A - Z)
  8. Propylthiouracil – Uses, Dosage, Side Effects, Interactions

    DefinitionPropylthiouracil is a Thyroid? Hormone Synthesis Inhibitor. The mechanism of action of propylthiouracil is as a Thyroid Hormone Synthesis Inhibitor. 6-propyl-2-thiouracil is a pyrimidine-thione consisting of uracil in which the...

    October 20, 2023 • Drugs (A - Z)
  9. Methimazole

    DefinitionMethimazole ( Metirox 5 and 10 mg) is a member of the class of imidazoles that it imidazole-2-thione in which a methyl group replaces the hydrogen that is attached to...

    October 20, 2023 • Drugs (A - Z)
  10. Mirogabalin – Uses, Dosage, Side Effects, Interactions

    DefinitionMirogabalin has been used in trials studying the treatment of Post-herpetic Neuralgia, Pain? Associated With Fibromyalgia, and Diabetic peripheral neuropathic pain. Mirogabalin is a medication designed...

    August 12, 2023 • Drugs (A - Z)